Document Detail

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party.
MedLine Citation:
PMID:  10090926     Owner:  NLM     Status:  MEDLINE    
We report the results of the first prospective randomized multicenter study of immunosuppressive treatment in patients with previously untreated nonsevere aplastic anemia (AA) as defined by a neutrophil count of at least 0.5 x 10(9)/L and transfusion dependence. Patients were randomized to receive cyclosporin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux, Lyon, France) and CSA. The endpoint of the study was the hematologic response at 6 months. One hundred fifteen patients were randomized and assessable with a median follow-up period of 36 months; 61 received CSA and 54 ATG and CSA. In the CSA group, the percentage of complete and partial responders was 23% and 23%, respectively, for an overall response rate of 46%. A significantly higher overall response rate of 74% was found in the ATG and CSA group, with 57% complete and 17% partial responders (P =. 02). Compared with CSA alone, the combination of ATG and CSA resulted in a significantly higher median hemoglobin level and platelet count at 6 months. Fewer patients required a second course of treatment before 6 months due to a nonresponse. In the CSA group, 15 of 61 (25%) patients required a course of ATG before 6 months because of disease progression, compared with only 3 of 54 (6%) in the ATG and CSA group. The survival probabilities for the two groups were comparable, 93% (CSA group) and 91% (ATG and CSA group), but at 180 days, the prevalence of patients surviving free of transfusions, which excluded patients requiring second treatment because of nonresponse, death, disease progression, or relapse, was 67% in the CSA group and 90% in the ATG and CSA group (P =.001). We conclude that the combination of ATG and CSA is superior to CSA alone in terms of the hematologic response, the quality of response, and early mortality, and a second course of immunosuppression is less frequently required.
J Marsh; H Schrezenmeier; P Marin; O Ilhan; P Ljungman; S McCann; G Socie; A Tichelli; J Passweg; J Hows; A Raghavachar; A Locasciulli; A Bacigalupo
Related Documents :
23541266 - Relationship between low-density lipoprotein levels on admission and 1-year outcome in ...
24560466 - Glenoid perforation does not affect the short-term outcomes of pegged all-polyethylene ...
20155706 - Evaluation of the effect of topical cyclosporine a with impression cytology in dry eye ...
23957946 - Long-term continence outcomes in men undergoing radical prostatectomy for clinically lo...
16080546 - Severity and duration of chronic dysphagia following treatment for head and neck cancer.
11052346 - Role of onlay grafting with minimal internal fixation for occipitocervical fusion in on...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Blood     Volume:  93     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-04-19     Completed Date:  1999-04-19     Revised Date:  2006-12-08    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2191-5     Citation Subset:  AIM; IM    
Department of Haematology, St George's Hospital Medical School, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anemia, Aplastic / drug therapy*,  mortality,  therapy
Antilymphocyte Serum / therapeutic use*
Blood Transfusion
Combined Modality Therapy
Cyclosporine / administration & dosage,  therapeutic use*
Drug Therapy, Combination
Europe / epidemiology
Hemoglobins / analysis
Immunosuppressive Agents / administration & dosage,  therapeutic use*
Life Tables
Middle Aged
Platelet Count
Prospective Studies
Survival Analysis
Survival Rate
T-Lymphocytes / immunology*
Treatment Outcome
Reg. No./Substance:
0/Antilymphocyte Serum; 0/Hemoglobins; 0/Immunoglobulins; 0/Immunosuppressive Agents; 0/lymphoglobuline; 59865-13-3/Cyclosporine
Comment In:
Blood. 1999 Sep 1;94(5):1833-4   [PMID:  10507843 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial...
Next Document:  Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with bu...